Groupama announces its Half Year Financial Report for 2026 is now available on its website and has been filed with the French stock exchange regulatory authority, l’Autorité des Marchés Financiers.

This document includes the half year 2026 combined financial statements, the half year activity report, the declaration by the person responsible for the Half Year Financial Report as well as the statutory auditors’ review on the half year financial information.

The Half Year Financial Report can be viewed in French on Groupama’s website (www.groupama.com), under the « Analyst / Results » section. The English version will be available on 28 September 2026.

Attachment

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform

WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults1.

With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a pre-cancerous skin condition, actinic keratosis (AK), and a skin cancer. The sBCC indication expands the addressable market for Ameluz and strengthens its position in medical dermatology. This label expansion also furthers Biofrontera’s strategy of broadening the clinical utility of its Red-Light PDT platform. Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, stated: “FDA approval of Ameluz for superficial basal cell carcinoma is a defining milestone for Biofrontera. Ameluz is now the first and only photodynamic therapy approved in the United States to treat a skin cancer, which sets our platform apart in medical dermatology and gives dermatologists an effective, non-surgical option for a very common tumor. This approval reflects years of disciplined investment in the clinical development of Ameluz, and the latest stage in the ongoing expansion of our PDT platform.” He added “We are planning an official launch of the sBCC indication late in the fourth quarter of 2026 through the first quarter of 2027 with our existing commercial organization and installed lamp base. We believe the approval represents a further driver of long-term growth for our existing customers. It also gives new Dermatology practices a reason to purchase a RhodoLED lamp and begin to use Ameluz PDT, expanding our overall installed base.” This new indication utilizes the same topical product (Ameluz) and the same red-light device as the Company’s AK indication, so our existing customers will be able to rapidly adopt this new treatment option.

Basal cell carcinoma (BCC) is the most common skin cancer in the United States, with approximately 3.6 million cases diagnosed annually, according to the Skin Cancer Foundation. Published estimates suggest that the superficial subtype accounts for approximately 15%-20% of BCC cases, or an estimated 540,000 to 720,000 sBCC cases annually in the U.S.2. Superficial BCC lesions can be up to several cm in diameter and are frequently located on the trunk and extremities and often present as multiple lesions, for which non-surgical, tissue-sparing treatment options are limited.

The approval is supported by a multicenter, randomized, double-blind, vehicle-controlled Phase 3 trial in 187 adults with histologically confirmed sBCC. The primary endpoint was a composite of both clinical and histological complete response of a main target lesion 12 weeks after the start of the last PDT cycle. This rigorous target was achieved in 66% of subjects treated with Ameluz PDT (95/145) compared with 5% of subjects treated with placebo-PDT (2/42). Histological clearance of the main target lesion was seen in 76% of Ameluz PDT treated patients versus 19% with Placebo-PDT, and 83% of Ameluz-treated subjects achieved complete clinical clearance of all target lesions compared with 21% for Placebo-PDT. The most common adverse reactions were application-site reactions consistent with the known safety profile of Ameluz PDT.

Dr. M. Shane Chapman, MBA, board certified dermatologist, Professor and Founding Chair, Department of Dermatology, Dartmouth Hitchcock Medical Center and the Dartmouth Geisel School of Medicine, and a key contributor to the Phase 3 study added “For many patients with superficial basal cell carcinoma — those with multiple lesions, lesions in cosmetically sensitive locations, or for whom surgery would not be preferred — treatment options have been limited. This FDA approval for Ameluz® and the RhodoLED gives us a rigorously studied, non-surgical option that we can deliver in our office. As someone who has worked with PDT for many years, I see this as a meaningful expansion in the use of this treatment.”

1 Ameluz Prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208081s040lbl.pdf)
2 Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147(1):41–47

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and superficial basal cell carcinoma, and are in development for additional indications. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Investor Contact

Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, in this press release, including statements regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “believe”, “anticipate”, “intend”, “expect”, “target”, “goal”, “estimate”, “plan”, “assume”, “may”, “will”, “predict”, “project”, “would”, “could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should read this press release and any documents referenced herein completely and with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our ability to achieve and sustain profitability; our ability to compete effectively in selling our products; our ability to expand, manage and maintain our direct sales and marketing efforts, including our ability to obtain the financing to develop our marketing strategy, if needed; changes in our relationship with our manufacturing partners and the possible impact of tariffs; our ability to manufacture our products; our ability to adequately protect our intellectual property and operate the business without infringing upon the intellectual property rights of others; our actual financial results may vary significantly from forecasts and from period to period; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation and group purchasing organizations (“GPOs”) in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third-party payors for our products, or procedures using our products significantly declines; our ability to market, commercialize, achieve market acceptance for and sell our products; the fact that product quality issues or product defects may harm our business; any claims brought against the Company, including but not limited to product liability claims, claims of patent infringement, or claims challenging the validity of our intellectual property; our ability to maintain compliance with The Nasdaq Stock Market, LLC continued listing standards; our ability to comply with the requirements of being a public company; the progress, timing and completion of research, development and preclinical studies and clinical trials for our products; our ability to obtain and maintain the regulatory approvals necessary for the marketing of our products in the United States; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (“SEC”), which can be obtained on the SEC website at www.sec.gov. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

Omni One Orders Increase Threefold Following Meta Launch

Company Advances Defense Programs, Enterprise Sales and Acquisition Strategy

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today provided an update on the strength of its business and progress across its consumer, defense, and enterprise markets, as well as its acquisition strategy.

The number of Omni One orders is up approximately 3X quarter-to-date compared to the same period last year, following the June launch of Omni One for Quest in collaboration with Meta. The acceleration builds on the momentum reported in Virtuix’s first fiscal quarter, when Omni One orders increased 72% year-over-year. The Company believes its integration with the Meta Quest ecosystem significantly expands Omni One’s addressable market and provides a strong foundation for continued consumer growth.

“We continue to see strong momentum across our core markets, with several key catalysts on the horizon,” said Jan Goetgeluk, Founder, Chairman and CEO of Virtuix. “Consumer demand has accelerated significantly following our Meta launch, our defense programs are progressing toward larger opportunities, and Omni One Enterprise is gaining traction across robotics, healthcare, and research. At the same time, we are advancing a potential strategic acquisition that we believe could meaningfully accelerate our revenues and expansion in the defense market.”

Defense Programs Progress Toward Larger Contract Opportunities

Virtuix continues to advance multiple programs with the U.S. Department of Defense. During the current quarter, the Company received its first contract revenue from the U.S. Air Force under its AFWERX Small Business Innovation Research (“SBIR”) Phase I award for Virtuix’s Virtual Terrain Walk (“VTW”) platform. Virtuix expects to complete Phase I this month and intends to submit a proposal for Phase II with support from several U.S. Air Force squadrons and departments. Phase II awards can provide up to approximately $2 million in additional funding and would enable the Company to further deploy its VTW technology for military mission-planning applications.

Virtuix is also showcasing its Counter-Unmanned Aircraft System (C-UAS) Personnel Trainer this week at the Maneuver Warfighter Conference, where U.S. Army and Joint leaders gather to examine current and future requirements of the maneuver force. Developed in collaboration with LeadTech and integrating Omni One, the system enables warfighters to physically maneuver through realistic virtual environments while training to detect and defeat hostile drones.

In addition, Virtuix is advancing its four-person Infantry Fireteam Trainer for the U.S. Marine Corps, with installation at Quantico, Virginia expected later this year. These initiatives form part of Virtuix’s strategy to progress from initial development programs and system deployments toward larger, multi-unit defense contracts.

Virtuix’s defense footprint now includes programs, sales, and collaborations across all four major branches of the U.S. military. Recent milestones include the Air Force SBIR award; appointment as lead systems integrator for the Marine Corps Infantry Fireteam Trainer; entry into counter-drone training; deployments with the U.S. Navy, U.S. Air Force Academy, U.S. Military Academy at West Point, Air National Guard, and Yokota Air Base in Japan; and a cooperative research and development agreement with the U.S. Navy.

Acquisition Strategy Could Accelerate Defense Expansion

Virtuix continues to actively pursue strategic acquisitions in the defense sector and is in advanced negotiations regarding a potential transaction with a target whose annual revenues are near the upper end of the Company’s previously announced target range of $10 million to $50 million, at a valuation and financing structure that, if completed, the Company believes could create significant value for Virtuix shareholders.

Beyond the potential addition of substantial revenue, Virtuix believes a strategic defense acquisition could provide significant benefits through established contract vehicles, past performance, customer relationships, and sales channels across the U.S. Department of Defense. These capabilities could help accelerate Virtuix’s ability to pursue larger contracts for its existing defense technologies, including Virtual Terrain Walk and counter-UAS applications.

The potential transaction remains subject to negotiation, due diligence, definitive agreements, financing, and customary closing conditions, and there can be no assurance that a transaction will be completed.

Enterprise Demand Grows with Follow-On Robotics Sales

Virtuix is also experiencing growing demand for Omni One Enterprise, its commercial platform for industrial training, healthcare, research, AI, robotics and other professional applications. During this quarter, Tesla, Inc. placed repeat Omni One Enterprise orders for use in its Optimus humanoid robot program. Figure AI, another company developing humanoid robots, also purchased Omni One Enterprise, further validating Omni One’s potential role in the rapidly developing embodied-AI and humanoid-robotics markets.

Omni One Enterprise has also been gaining traction in the fields of industrial training, healthcare, and research, with multiple systems sold this quarter to NASA, KBR, Sirica Therapeutics, and various research institutions. Virtuix believes these emerging applications represent an additional, high-margin growth market for its technology beyond its established consumer gaming and defense businesses.

The Company believes the combination of accelerating consumer demand, progression toward larger defense contracts, expanding enterprise adoption, and a potential strategic acquisition positions Virtuix to pursue multiple growth opportunities over the coming quarters.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations for continued consumer growth following the Meta integration; the timing, completion, funding, or scope of defense programs, including the AFWERX SBIR Phase II proposal and the Infantry Fireteam Trainer installation; the Company’s ability to progress from initial development programs toward larger defense contracts; the Company’s sales and expansion plans; plans to pursue and complete strategic acquisitions, including the potential transaction currently under negotiation; potential impacts of any acquisition on future revenues, operations, or shareholder value; the Company’s competitive position in the defense training market; and the potential for enterprise applications to represent an additional growth market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business and realize anticipated synergies or benefits; risks related to government contracting, including contract cancellations, modifications, delays, or funding changes; uncertainties regarding continued consumer demand and market acceptance of the Company’s products; competition in the VR, gaming, defense, and enterprise markets; dependence on third-party relationships, including the Meta partnership; the uncertainties related to general market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

KNOXVILLE, Tenn., Sept. 14, 2026 (GLOBE NEWSWIRE) — SafeSpace Global Corporation (OTCID: SSGC) (“SafeSpace Global” or the “Company”), a publicly traded, applied multimodal AI-powered physical safety and security technology company, today announced the completion and successful installation of its integrated school-safety solution in its first K-12 campus in Connecticut.

The deployment uses SafeSpace Global’s camera-agnostic, applied multimodal AI platform to support facial-recognition and weapons-detection applications as part of the school’s broader campus-safety initiative. To protect the privacy and safety of students and staff, the name and specific location of the participating school are not being disclosed.

The installation advances the Company’s mission to help protect lives by supporting earlier threat detection and faster, more informed emergency response.

How the Integrated Solution Works

SafeSpace Global’s integrated solution is designed around a critical principle: identifying a potential threat early, detecting it quickly and providing actionable information to the appropriate personnel can help improve emergency-response times.

The solution operates through four connected steps:

  1. Identification: SafeSpace Global’s visual AI monitors configured camera feeds to identify person, places, or things. 
  2. Detection: When the platform detects a potential threat, it generates an alert that includes available location information.
  3. Alert- Human verification: A trained human reviewer evaluates the alert to help reduce false-positive escalations and determine whether further action is appropriate.
  4. Notification and activation: Once a threat is confirmed, the platform can initiate configured incident-response workflows. Depending on the customer’s systems and protocols, these workflows may include notifying designated school personnel, alerting local authorities, initiating lockdown procedures and providing location intelligence to first responders.

Through its strategic integrations, SafeSpace Global delivers an end-to-end capability designed to shorten the time between initial identification, detection, verification and response.

“This first K-12 installation represents an important milestone for SafeSpace Global and demonstrates how our technology can be deployed within a school’s existing security infrastructure,” said Scott M. Boruff, Founder and Chief Executive Officer of SafeSpace Global Corporation. “Our objective is straightforward: help schools identify potential threats earlier, verify alerts quickly and provide actionable information to the people responsible for responding. We believe bringing these capabilities together can give administrators and first responders more time to act when seconds matter.”

What SafeSpace Global Does

SafeSpace Global provides AI-powered physical-security technology designed to help make everyday environments safer. Its visual AI integrates with a facility’s existing camera infrastructure to identify potential weapons and other designated threats, present alerts for rapid human verification and transmit verified incidents to integrated response platforms.

SafeSpace Global serves multiple sectors, including K-12 education, senior living, addiction-treatment facilities, correctional facilities and faith-based organizations. Its solutions focus on proactive threat identification and providing organizations with actionable information before an incident escalates.

About SafeSpace Global Corporation

SafeSpace Global Corporation (OTCID: SSGC) is a publicly traded technology company providing proprietary, applied multimodal, AI-powered physical safety solutions in its mission to help save lives. Headquartered in Knoxville, Tennessee, the Company has its Tennessee AI Center of Excellence and regional office in Nashville, Tennessee. Learn more at www.SafeSpaceGlobal.ai.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. SafeSpace Global undertakes no obligation to update or revise any forward-looking statements except as required by applicable law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Investor Relations:
Michael Hrynuik
SafeSpace Global Corporation
michael.hrynuik@safespaceglobal.ai
917-885-1174

Media Contact:
Nicole Beal
SafeSpace Global Corporation
marketing@safespaceglobal.ai

Bagsværd, Denmark, 14 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 07 September, the following transactions have been made:

  Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 17,275,000   5,221,774,293
7 September 2026 210,000 297.98 62,576,264
8 September 2026 210,000 295.53 62,062,090
9 September 2026 210,000 289.37 60,767,699
10 September 2026 210,000 288.08 60,496,529
11 September 2026 210,000 278.62 58,509,613
Accumulated under the programme 18,325,000   5,526,186,488

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 47,124,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 11 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 33,084,179 B shares at an average share price of DKK 281.89 per B share equal to a transaction value of DKK 9,326,186,478.

Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Nordisk Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com

 

Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com

 

Novo Nordisk Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com

 

Sina Meyer
+45 3079 6656
azey@novonordisk.com

 

Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com

 

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

 

Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com

 

Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

 

Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Company announcement No 55 / 2026

Attachments

Previously announced follow-on orders from an existing governmental intelligence customer reflect continued operational use of Maris-Tech’s edge video and AI technology in mission-critical, bandwidth-constrained environments

Rehovot, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global provider of video and artificial intelligence (“AI”)-based edge computing technology, today provided an update highlighting a series of previously announced orders from an existing governmental customer operating in the intelligence gathering domain, including follow-on orders announced in June 2026 and an additional follow-on order announced in August 2026.

The June orders extended the ongoing deployment of Maris-Tech’s edge video and AI systems and reflected continued operational use in mission-critical environments. The August order continued a series of product deployments with the same customer, which is already operating Maris-Tech systems in the field for intelligence gathering applications, and followed earlier orders announced in March, April and June 2026.

Taken together, the orders reinforce the customer’s sustained use of the Company’s solutions for real-time video capture, processing and transmission directly at the point of collection, including in bandwidth-constrained conditions.

Israel Bar, Chief Executive Officer of Maris-Tech, said: “The repeat orders we have received from a customer already operating our systems in the field are the clearest signal we can ask for. An additional order from that same customer provides meaningful validation of both the technology and our ability to support its operational requirements. We believe these previously announced orders demonstrate how our solutions perform when they matter.”

Maris-Tech continues to support intelligence and defense-related applications with edge-based video and AI technologies designed for deployment in complex operational conditions.

About Maris-Tech Ltd.

Maris-Tech is a global leader in video and AI-based edge computing technology, pioneering intelligent video transmission solutions that conquer complex encoding-decoding challenges. The Company’s miniature, lightweight, and low-power products deliver high-performance capabilities, including raw data processing, seamless transfer, advanced image processing, and AI-driven analytics. Founded by Israeli technology sector veterans, Maris-Tech serves leading manufacturers worldwide in defense, aerospace, intelligence gathering, homeland security, and communication industries. We’re pushing the boundaries of video transmission and edge computing, driving innovation in mission-critical applications across commercial and defense sectors.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect”,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief regarding the significance of previously announced repeat orders from an existing governmental intelligence customer, including the extent to which such orders validate the Company’s technology and its ability to support the customer’s operational requirements, and the Company’s ability to continue to support intelligence and defense-related applications with its edge-based video and AI technologies. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.

The company’s CEO, President and director, Amir F. Heshmatpour, just bought another 37,000 shares of NTHI at $3.6654 apiece, putting approximately $136,000 of his own money behind the stock and the timing is what makes this purchase particularly intriguing.

NeOnc had just announced a $15 million registered direct offering at $4.20 per share, meaning Heshmatpour’s latest purchase occurred at a substantial discount to the financing price.

That is not the kind of insider transaction small-cap biotech traders casually dismiss.

Heshmatpour has been buying NTHI repeatedly and he isn’t the only insider who has been putting money behind the company. In August, Heshmatpour bought additional shares, while founder and Chief Scientific Officer Thomas C. Chen also made substantial purchases.

The Clinical Catalyst

NeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. The company reported a 48.9% six-month progression-free survival rate, versus a pre-specified 20% benchmark.

Even more eye-catching: the company reported a 26.09-month median overall survival.

Five of 24 patients remained on treatment at the data cutoff, including one patient with progression-free survival approaching 19 months and another with an ongoing partial response. For a company operating in one of oncology’s toughest areas, those numbers naturally attracted attention, but the real story may be what comes next.

NeOnc says it plans to request a Type B meeting with the FDA to discuss the potential registrational path for NEO100. CEO Heshmatpour said the company’s priority is “to engage with the FDA and align on the most efficient path toward a registrational study,” which is a major potential inflection point.

If FDA discussions produce a viable path forward, NEO100 could move from an intriguing clinical-stage asset toward a potentially registrational development program, which makes the insider buying even more interesting, because Heshmatpour is buying after clinical data have been released and while the company is pursuing regulatory discussions.

The Blood-Brain Barrier

There is another piece investors cannot ignore: the blood-brain barrier.

Brain tumors are notoriously difficult to treat because getting drugs into the brain is itself a major challenge. NeOnc’s NEO100 program uses intranasal delivery designed to facilitate delivery to the brain through olfactory and trigeminal pathways.

If that approach can translate into meaningful clinical benefit, the opportunity could extend well beyond one small study.

NEO100’s Phase 2a study was small, open-label and single-arm. Larger studies are needed. FDA discussions do not guarantee a registrational pathway, or approval.

The company has simultaneously been advancing NEO100 and NEO212, raising capital and moving toward additional clinical and regulatory milestones.

For investors hunting for small-cap biotech names before major catalysts, that’s the part of the story that deserves attention, and if NEO100’s clinical signal ultimately translates into a successful registrational program, today’s insider buying could look considerably more significant in hindsight.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET

Management available for one-on-one meetings with investors during the conference

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, in New York City.

During the presentation, Mr. Luther will provide an overview of Ernexa’s focused oncology strategy and recent progress with ERNA-101, the Company’s lead oncology cell therapy candidate. The presentation will highlight Ernexa’s differentiated, off-the-shelf-induced mesenchymal stem cell, or iMSC, platform, the growing body of preclinical evidence supporting ERNA-101 and the Company’s planned transition toward clinical development.

Presentation Details for Conference Attendees:

Conference: H.C. Wainwright 28th Annual Global Investment Conference
Presenter: Sanjeev Luther, President & CEO
Date: Wednesday, September 16, 2026
Time: 12:00 p.m. ET
Location: Kennedy I, 4th Floor

In addition to the presentation, Ernexa management will be available for one-on-one meetings with qualified investors during the conference. Investors interested in meeting with Ernexa management are encouraged to contact their H.C. Wainwright representative to request a meeting.

For more information about the conference, please visit the conference website.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.
The partnership is based on a shared conviction: that innovative medicines and certain mature medicines have different needs and should benefit from operating models tailored to their specific manufacturing, regulatory and commercial requirements. Cheplapharm’s specialized expertise will ensure these medicines continue to meet patients’ needs throughout the next stage of their lifecycle.

“Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them. Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio. This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs,” said Thomas Grenier, Executive Vice President, General Medicines, Sanofi.

“This partnership marks a major milestone for Cheplapharm. Through this project, we are incorporating products that complement our extensive portfolio, as well as the expertise and manufacturing capabilities required to produce a flagship product, Lovenox®/Clexane®. This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients.” “We are proud to pursue this ambition alongside Sanofi,” said Edeltraud Lafer and Sebastian Braun, both Co-CEOs of Cheplapharm. 

As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees). The teams would continue their activities with existing employment arrangements and collective agreements maintained. Sanofi and Cheplapharm will work closely together to ensure a smooth transition and continuity of supply in compliance with the highest manufacturing quality standards.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027, followed by the transfer of the sites, subject to employee information and consultation procedures with employee representatives, regulatory approvals and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.

For Cheplapharm, this partnership represents an important step ensuring the continuity of its strategic growth. For Sanofi, it will enable the company to continue focusing its efforts on innovation, while supporting certain established medicines through the next stage of their lifecycle.

Financial considerations for Sanofi 
The proposed transaction is not expected to have any impact on Sanofi’s financial guidance for 2026. The medicines being divested from Sanofi include Lovenox/Clexane (enoxaparin)1. Additional financial details are expected to be provided at a later stage.

 [1] Excluding in the US.

 

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Cheplapharm 
Cheplapharm  is a European family-owned pharmaceutical company based in Germany, specializing in well-established originator medicines. Driven by a long-term vision of sustainable growth, the Group has invested more than €6.2 billion since its inception, acquired nearly 100 products since 2015, and holds 3,440 marketing authorizations across 160 countries. Cheplapharm is the market leader in France and a leading European player in this market segment.

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Laura Romby | +33 6 74 16 74 29 |  laura.romby@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com 
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com 

Investor Relations
Thomas Kudsk Larsen | + 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Press contact Cheplapharm
Sandra Ammara : +33 6 79 92 71 34 – communication@cheplapharm.fr 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. 
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” “outlook,” “guidance,” or the negative of these, and similar expressions are intended to identify forward-looking statements. 
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete capital markets or other transactions, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with developing standalone businesses and with intellectual property, as well as any related pending or future litigation and the ultimate outcome of such litigation; and other risks associated with  trends in exchange and interest rates, volatile economic, political and financial and market conditions, cost containment initiatives, and the impact that global crises may have. More specifically regarding the transaction described above, these risks and uncertainties include among other things the possibility that the transaction will not be completed, or if completed, will not be completed in the expected timeframe, an unexpected failure to satisfy the required closing conditions, or unexpected delays in meeting these requirements, the ability to obtain regulatory clearances, the possibility that the expected strategic benefits, synergies or opportunities from the transaction may not be realized, or may take longer to realize than expected. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. 
All trademarks mentioned in this press release are the property of the Sanofi group.

 

Attachment

Founder and CEO outlines NextNRG’s vision, technology platform and path forward

MIAMI, FL, Sept. 14, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (Nasdaq: NXXT) (“NextNRG” or the “Company”), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced that Founder and Chief Executive Officer, Michael D. Farkas, has issued the following letter to the Company’s shareholders outlining his perspective on NextNRG’s business, technology platform and opportunities ahead:

Letter to Our Shareholders

I have spent the better part of my career building companies in industries that were changing before the market fully understood where they were going. I founded NextNRG with the same conviction: that the way businesses produce, store and use energy is changing, and that the companies willing to build for that future will have an opportunity to create lasting value.

I still believe that as strongly as I did when we started. I want to take this opportunity to speak directly to you about where we are headed.

The market will always put a price on a company. Our job is to build the company that ultimately determines what that price is worth. That is where my focus is.

NextNRG is building an integrated energy platform around a simple idea: businesses need more agency over how they generate, store and use energy. Our opportunity is to bring together the technology, infrastructure and operating capabilities to help them do that.

We have spent years building the foundation for that opportunity. We have developed technology, established an operating business, secured agreements and developed a pipeline of projects that we believe can become sources of future revenue, including, in the healthcare sector alone, multiple facility projects at different stages of development.

Projects like these take real time to move from an agreement to operational, and that timeline is not always visible from the outside. But the work behind the scenes is real, and it is where our team remains focused.

And we are beginning to see opportunities to extend the value of capabilities we have already built beyond their original purpose.

That is how I think about NextNRG’s future. We are building on what we have already created while continuing to look for opportunities to expand the value of our technology and infrastructure. The goal is not to chase every opportunity. It is to build businesses around capabilities we believe have real value, and to execute against opportunities we believe make sense for NextNRG.

There is more in the pipeline, and we will announce each project when it is signed, not before. Our focus is on turning the opportunities in front of us into operating projects and new sources of revenue.

I founded NextNRG. I am deeply invested in its future, and I have not sold a share of my position.

Our job now is to execute and be straightforward with our shareholders about how it is going.

I believe in what we are building, and I believe the opportunity ahead of NextNRG is significant.

Michael D. Farkas

Founder and Chief Executive Officer

NextNRG, Inc.

About NextNRG, Inc.

NextNRG, Inc. (NextNRG) is Powering What’s Next by deploying its AI-driven Smart Controller, a proprietary AI technology that continuously optimizes how energy is generated, stored, and consumed. The Company deploys the controller within microgrids at commercial, healthcare, municipal, industrial and federal sites, and at a utility scale through the Next Utility Operating System®.

NextNRG also sells EV chargers, is advancing wireless in-motion charging, and operates one of the nation’s largest on-demand mobile fueling fleets through EzFill.

To learn more, visit www.nextnrg.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations ContactNextNRG, Inc.
Sharon Cohen
SCohen@nextnrg.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.